Nuclear Medicine and Biology
Volume 33, Issue 4 , Pages 449-451 , May 2006

Discussion of targeting proteins in vivo: in vitro guidelines

Received 15 March 2006 ,Revised 20 March 2006 ,Accepted 21 March 2006.

References 

  1. Eckelman WC, Receptor binding radiotracers, vols. I (p.1-80) and II (p.1-230). Boca Raton (Fla): CRC Press, 1982.
  2. Eckelman WC, Reba RC, Gibson RE, Rzeszotarski WJ, Vieras F, Mazaitis JK, et al. Receptor binding radiotracers: a class of potential radiopharmaceuticals. J Nucl Med. 1979;20:350–357
  3. Katzenellenbogen JA, Heiman DF, Carlson KE, Lloyd JE. In vitro and in vivo steroid receptor assays in the design of estrogen radiopharmaceuticals. In:  Eckelman WC editors. Receptor binding radiotracers. vol. I:Boca Raton (Fla): CRC Press; 1982;p. 93–126
  4. Selikson M, Gibson RE, Eckelman WC, Reba RC. Calculation of binding isotherms when ligand and receptor are in different volumes of distribution. Anal Biochem. 1980;108:64–71
  5. Kung MP, Kung HF. Mass effect of injected dose in small rodent imaging by SPECT and PET. Nucl Med Biol. 2005;32:673–678
  6. Motulsky HJ, Christopoulos A. Fitting models to biological data using linear and nonlinear regression.. In: A practical guide to curve fitting. San Diego (Calif): GraphPad Software Inc.; 2003;p. 187–193www.graphpad.com
  7. Kung MP, Choi SR, Hou C, Zhuang ZP, Foulon C, Kung HF. Selective binding of 2-[125I]iodo-nisoxetine to norepinephrine transporters in the brain. Nucl Med Biol. 2004;31:533–541
  8. Gotti C, Fornasari D, Clementi F. Human neuronal nicotinic receptors. Prog Neurobiol. 1997;53:199–237
  9. Loiacono R, Stephenson J, Stevenson J, Mitchelson F. Multiple binding sites for nicotine receptor antagonists in inhibiting [3H](−)nicotine binding in rat brain. Neuropharm. 1993;32:847–853
  10. Sihver W, Nordberg A, Langstrom B, Mukhin AG, Koren AO, Kimes AS, et al. Development of ligands for in vivo imaging of cerebral nicotinic receptors. Behav Brain Res. 2000;113:143–157
  11. Brown-Proctor C, Snyder SE, Sherman PS, Kilbourn MR. Synthesis and in vivo evaluation of (E)-N-[11C]methyl-4-(3-pyridinyl)-3-butene-1-amine ([11C]metanicotine) as a nicotinic receptor radioligand. Nucl Med Biol. 2000;27:415–418
  12. Roger G, Lagnel B, Rouden J, Besret L, Valette H, Dempel S, et al. Synthesis of a [2-pyridinyl-18F]-labeled fluoro derivative of (−)-cytisine as a candidate radioligand for brain nicotinic α4β2 receptor imaging with PET. Bioorg Med Chem. 2003;11:5333–5343
  13. Banerjee S, Punzi JS, Kreilick K, Abood LG. [3H]mecamylamine binding to rat brain membranes. Studies with mecamylamine and nicotine analogues. Biochem Pharmacol. 1990;40:2105–2110
  14. Christian BT, Narayanan T, Shi B, Morris ED, Mantil J, Mukherjee J. Measuring the in vivo binding parameters of [18F]-fallypride in monkeys using a PET multiple-injection protocol. J Cereb Blood Flow Metab. 2004;24:309–322
  15. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959–1972
  16. Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci. 2005;25:10598–10606
  17. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46:2740–2754

PII: S0969-8051(06)00065-5

doi: 10.1016/j.nucmedbio.2006.03.008

Nuclear Medicine and Biology
Volume 33, Issue 4 , Pages 449-451 , May 2006

Article Tools